K
Kalgi Mody
Researcher at Eisai
Publications - 20
Citations - 1737
Kalgi Mody is an academic researcher from Eisai. The author has contributed to research in topics: Lenvatinib & Pembrolizumab. The author has an hindex of 6, co-authored 11 publications receiving 452 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn,Masafumi Ikeda,Andrew X. Zhu,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Kalgi Mody,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC, and toxicities were manageable, with no unexpected safety signals.
Journal ArticleDOI
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Richard S. Finn,Masatoshi Kudo,Philippe Merle,Tc Meyer,S. Qin,Masahumi Ikeda,Rui-Hua Xu,Julien Edeline,Baek-Yeol Ryoo,Zhenggang Ren,A. Cheng,Peter R. Galle,Syuuichi Kaneko,Hiromitsu Kumada,A. Wang,Kalgi Mody,Leonid Dubrovsky,Abby B. Siegel,Josep M. Llovet +18 more
TL;DR: The global, randomized, double-blind, Ph3 LEAP-002 study (NCT03713593) as mentioned in this paper evaluated the efficacy and safety of lenvatinib + pembrolizumab (lenva + pembro) vs. placebo as 1L therapy for aHCC.
Journal ArticleDOI
A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Josep M. Llovet,K.V. Shepard,Richard S. Finn,Masafumi Ikeda,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,M. Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Kalgi Mody,Tomoki Kubota,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Andrew X. Zhu +19 more
TL;DR: Lencioni et al. as mentioned in this paper reported results from a phase 1b trial of LEN + PEMBRO in uHCC, 104 patients with BCLC stage B (not amenable for transarterial chemoembolization) or C, Child-Pugh class A, and ECOG PS≤1 received LEN (body wt≥60kg: 12mg/day).
Journal ArticleDOI
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
Andrew X. Zhu,Richard S. Finn,Masafumi Ikeda,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Kalgi Mody,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Josep M. Llovet +19 more
TL;DR: LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1-4, PDGFRα, RET, and KIT, approved for first line treatment of uHCC and PEMBRO, an anti-PD-1 monoclonal antibody, was granted accelerated approval.